Alan Ezekowitz, MD, DPhil, is an Advisory Partner at Third Rock Ventures and formerly Interim Chief Medical Officer at Septerna. Dr. Ezekowitz is a physician scientist, who spent the first 20 years of his career as a clinical leader in health care systems where he established himself as a leader in the field of developmental immunology. Prior to joining Third Rock, Dr. Ezekowitz was Co-Founder and CEO of Abide Therapeutics, which was acquired by Lundbeck Pharmaceuticals. Before co-founding Abide, he was a Senior Vice President at Merck responsible for the Bone, Respiratory, Immunology, Inflammation, Dermatology, and Woman’s Health franchises. Earlier in his career, Dr. Ezekowitz served at the Harvard Medical School as the Charles Wilder Professor of Pediatrics, as the Head of Laboratory for Development Immunology and Principal of the Cancer Center and later as Chief of Pediatric Services at the Massachusetts General Hospital for Children, and as a director on the Partners Healthcare System board. In addition to Septerna, Dr. Ezekowitz currently serves on the boards of Fulcrum Therapeutics and Organon.
Dr. Ezekowitz received his MD from the University of Cape Town in South Africa and earned his DPhil in Cellular and Molecular Biology at the University of Oxford.